Patients diagnosed or treated for malignancy other than MCL are not eligible unless they meet one of the following exceptions:\r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before registration and felt to be at low risk for recurrence by the treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
History of other malignancy within the past 2 years prior to first dose of AMG 757 except: Malignancy (other than in situ) treated with curative intent and with no known active disease present for . 2 years before first dose of AMG 757 and felt to be at low risk for recurrence by the treating physician. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately treated in situ cancer without evidence of disease. Prostatic intraepithelial neoplasia without evidence of prostate cancer Adequately treated urothelial papillary noninvasive carcinoma
History of other malignancies, except: \r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
History of other malignancy within the past 2 years prior to enrollment except: Malignancy (other than in situ) treated with curative intent and with no known active disease present for ? 2 years before enrollment and felt to be at low risk for recurrence by the treating physician; Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; Adequately treated in situ cancer without evidence of disease; Prostatic intraepithelial neoplasia without evidence of prostate cancer; Adequately treated urothelial papillary noninvasive carcinoma.
History of prior malignancy, with the exception of the following: malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician; or adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled non-melanomatous skin cancer; or adequately treated cervical carcinoma in situ without current evidence of disease.
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
Malignancy treated with curative intent and with no known active disease present for ? 3 years before enrollment and felt to be at low risk for recurrence by the treating physician.
History of other malignancies, except: \r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo malignancy without evidence of disease\r\n* Adequately treated carcinoma in situ or T1 urothelial cancer without evidence of disease
Patients diagnosed or treated for malignancy other than HCC are not eligible unless they meet one of the following exceptions:\r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before registration and felt to be at low risk for recurrence by the treating physician.\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
History of other malignancy within the past 3 years except treated with curative intent and no known active disease present and has not received chemotherapy for >= 1 year before enrollment/randomization and low risk for recurrence
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
Presence of a malignant disease within the last 12 months, with the exception of adequately treated in-situ carcinomas, basal or squamous cell carcinoma, non-melanomatous skin cancer, or malignancies treated with curative intent and no evidence of active disease in prior 12 months and felt to be low risk for recurrence.
Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician
Malignancy treated with curative intent and with no known active disease present for ? 3 years before enrollment and felt to be at low risk for recurrence by the treating physician
No prior malignancy with the exceptions listed below:\r\n* Malignancy treated with curative intent and with no evidence of active disease for more than 3 years prior to screening and felt to be at low risk (< 30%) for recurrence by the treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
History of prior malignancy, with the exception of the following:\r\n* Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
Any prior history of other malignancy besides follicular lymphoma, unless the patient has been free of disease for >= 5 years and felt to be at low risk for recurrence by the treating physician, except:\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
History of other malignancies, except: \r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease
History of other malignancies, except: malignancy treated with curative intent and with no known active disease present for >= 5 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician, (2) adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, (3) adequately treated carcinoma in situ without evidence of disease, or (4) Gleason 6 prostate cancer under observation
Any prior history of other malignancy besides FL or marginal zone lymphoma, unless the patient has been free of disease for >= 5 years and felt to be at low risk for recurrence by the treating physician, except:\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
Subjects with a history of malignancy are not eligible with the exception of the following:\r\n* Malignancy treated within curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
History of prior malignancy, with the exception of the following:\r\n* Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening, and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
History of other malignancy, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years prior to randomization and felt to be at low risk for recurrence by the treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
Any prior or synchronous malignancy (other than breast cancer), except i) Malignancy treated with curative intent and with no evidence of disease for ? 5 years prior to enrollment and considered to be at low risk for recurrence by the treating physician ii) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
Malignancy treated with curative intent and with no known active disease present for ?3 years before the first dose of study drug and with low risk of recurrence by treating physician.
History of prior malignancy, with the exception of the following:\r\n* Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
History of prior malignancy, with the exception of the following:\r\n* Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease\r\n* Skin-limited Kaposi sarcoma that has not required systemic treatment within 6 months prior to study enrollment
Malignancy treated with curative intent and with no known active disease present for ?5 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
History of prior malignancy, with the exception of the following:\r\n* Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease\r\n* Adequately treated cervical carcinoma in situ without current evidence of disease
History of other malignancy, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years prior to registration and felt to be at low risk for recurrence by the treating physician\r\n* Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated cervical carcinoma in situ without evidence of disease
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >= 1 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease\r\n* Low-risk prostate cancer after curative surgery
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease\r\n* Low-risk prostate cancer on active surveillance
EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): History of other malignancies, except: \r\n* Malignancy treated with curative intent and with no known active disease present for >= 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n Adequately treated carcinoma in situ without evidence of disease
History of other malignancies, except: malignancy treated with curative intent and with no known active disease present for >= 5 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician, (2) adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, (3) adequately treated carcinoma in situ without evidence of disease, or (4) Gleason 6 prostate cancer under observation
History of other malignancies, except:\r\n* Malignancy treated with curative intent and with no known active disease present before the first dose of study drug and felt to be at low risk for recurrence by treating physician\r\n* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\r\n* Adequately treated carcinoma in situ without evidence of disease\r\n* Low-risk prostate cancer on active surveillance
History of other malignancy within the past 5 years with the following exception: . malignancy treated with curative intent and with no known active disease present and has not received chemotherapy for > 5 years before enrollment and felt to be at low risk for recurrence by the treating physician.
